title: Barrett's esophagus: a retrospective analysis of 13 years surveillance.
abstract: OBJECTIVE
  The incidence of esophageal adenocarcinoma has increased significantly. Barrett's esophagus (BE), a known precursor, has a high prevalence but only few patients with this condition progress to malignancy--surveillance and screening programs are controversial and lack proven efficacy. This retrospective analysis reviews the 13-year outcome for patients entered into a surveillance program.
  
  
  METHODS
  Data from patients with histologically proven Barrett's esophagus (1992-2003) that participated in a surveillance program were identified and analyzed retrospectively until 2005.
  
  
  RESULTS
  404/536 patients had Barrett's esophagus confirmed histologically of which 212 (53%) were followed in a surveillance program (mean 3.95 years per patient). This resulted in 749 gastroscopies (3.5/patient). Histologically, Barrett's mucosa was seen in 54%, low-grade dysplasia in 18%, ulcerations in 9%, high-grade dysplasia in 2%. No metaplasia was seen in 13%, no biopsy was obtained in 3%. Nine of 212 patients (4.3%) under surveillance developed esophageal cancer; two presented with symptoms, requiring gastroscopy outside the surveillance program (1/2 was operated successfully, one had advanced disease). In seven asymptomatic patients, cancer was detected on routine endoscopy; curative esophagectomy was performed in six. All patients who developed cancer were male and all but one patient had dysplasia or ulcerations on index endoscopy.
  
  
  CONCLUSIONS
  During 13 years of Barrett's surveillance, 88% of all adenocarcinoma occurred in a subset of only 11% patients. To stratify surveillance for Barrett's esophagus, programs could focus on male patients with dysplasia or ulcerations on index endoscopy. However, the cost-effectiveness of this remains unproven.
authors.affiliation: Department of Medical and Surgical Sciences, Medicine Section, University of Otago Medical School, Dunedin, New Zealand.
authors.forename: Victoria
authors.initials: V
authors.lastname: Switzer-Taylor
authors.forename: Martin
authors.initials: M
authors.lastname: Schlup
authors.forename: Ralf
authors.initials: R
authors.lastname: Lübcke
authors.forename: Vicki
authors.initials: V
authors.lastname: Livingstone
authors.forename: Michael
authors.initials: M
authors.lastname: Schultz
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology* / Q000601:surgery; D000368:Aged; D000369:Aged, 80 and over; D001471:Barrett Esophagus / Q000473:pathology*; D001706:Biopsy; D018450:Disease Progression; D004938:Esophageal Neoplasms / Q000473:pathology* / Q000601:surgery; D016629:Esophagectomy; D004945:Esophagoscopy; D004947:Esophagus / Q000473:pathology*; D005260:Female; D005773:Gastroscopy; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000379:methods; D008875:Middle Aged; D009092:Mucous Membrane / Q000473:pathology; D018579:Patient Selection; D011230:Precancerous Conditions / Q000473:pathology*; D015397:Program Evaluation; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D012737:Sex Factors; D014456:Ulcer / Q000473:pathology